Literature DB >> 15456870

RNA polymerase II carboxy-terminal domain phosphorylation is required for cotranscriptional pre-mRNA splicing and 3'-end formation.

Gregory Bird1, Diego A R Zorio, David L Bentley.   

Abstract

We investigated the role of RNA polymerase II (pol II) carboxy-terminal domain (CTD) phosphorylation in pre-mRNA processing coupled and uncoupled from transcription in Xenopus oocytes. Inhibition of CTD phosphorylation by the kinase inhibitors 5,6-dichloro-1beta-D-ribofuranosyl-benzimidazole and H8 blocked transcription-coupled splicing and poly(A) site cleavage. These experiments suggest that pol II CTD phosphorylation is required for efficient pre-mRNA splicing and 3'-end formation in vivo. In contrast, processing of injected pre-mRNA was unaffected by either kinase inhibitors or alpha-amanitin-induced depletion of pol II. pol II therefore does not appear to participate directly in posttranscriptional processing, at least in frog oocytes. Together these experiments show that the influence of the phosphorylated CTD on pre-mRNA splicing and 3'-end processing is mediated by transcriptional coupling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456870      PMCID: PMC517882          DOI: 10.1128/MCB.24.20.8963-8969.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

Review 1.  RNA polymerase II and the integration of nuclear events.

Authors:  Y Hirose; J L Manley
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

2.  Participation of the C-terminal domain of RNA polymerase II in exon definition during pre-mRNA splicing.

Authors:  C Zeng; S M Berget
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Capping, splicing, and 3' processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD.

Authors:  N Fong; D L Bentley
Journal:  Genes Dev       Date:  2001-07-15       Impact factor: 11.361

Review 4.  An extensive network of coupling among gene expression machines.

Authors:  Tom Maniatis; Robin Reed
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

5.  Requirements of the RNA polymerase II C-terminal domain for reconstituting pre-mRNA 3' cleavage.

Authors:  Kevin Ryan; Kanneganti G K Murthy; Syuzo Kaneko; James L Manley
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

Review 6.  Integrating mRNA processing with transcription.

Authors:  Nick J Proudfoot; Andre Furger; Michael J Dye
Journal:  Cell       Date:  2002-02-22       Impact factor: 41.582

7.  Coupled in vitro synthesis and splicing of RNA polymerase II transcripts.

Authors:  S Ghosh; M A Garcia-Blanco
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

8.  Dynamic association of capping enzymes with transcribing RNA polymerase II.

Authors:  S C Schroeder; B Schwer; S Shuman; D Bentley
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 9.  The mRNA assembly line: transcription and processing machines in the same factory.

Authors:  David Bentley
Journal:  Curr Opin Cell Biol       Date:  2002-06       Impact factor: 8.382

10.  The C-terminal domain of RNA polymerase II couples mRNA processing to transcription.

Authors:  S McCracken; N Fong; K Yankulov; S Ballantyne; G Pan; J Greenblatt; S D Patterson; M Wickens; D L Bentley
Journal:  Nature       Date:  1997-01-23       Impact factor: 49.962

View more
  53 in total

1.  Human T-lymphotropic virus type 1 Tax protein complexes with P-TEFb and competes for Brd4 and 7SK snRNP/HEXIM1 binding.

Authors:  Won-Kyung Cho; Moon Kyoo Jang; Keven Huang; Cynthia A Pise-Masison; John N Brady
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Nascent-seq indicates widespread cotranscriptional pre-mRNA splicing in Drosophila.

Authors:  Yevgenia L Khodor; Joseph Rodriguez; Katharine C Abruzzi; Chih-Hang Anthony Tang; Michael T Marr; Michael Rosbash
Journal:  Genes Dev       Date:  2011-12-01       Impact factor: 11.361

3.  Chromatin density and splicing destiny: on the cross-talk between chromatin structure and splicing.

Authors:  Schraga Schwartz; Gil Ast
Journal:  EMBO J       Date:  2010-04-20       Impact factor: 11.598

4.  The conserved AAUAAA hexamer of the poly(A) signal can act alone to trigger a stable decrease in RNA polymerase II transcription velocity.

Authors:  Anita Nag; Kazim Narsinh; Amir Kazerouninia; Harold G Martinson
Journal:  RNA       Date:  2006-06-14       Impact factor: 4.942

5.  Distal regulation of alternative splicing by splicing enhancer in equine beta-casein intron 1.

Authors:  Tina Lenasi; B Matija Peterlin; Peter Dovc
Journal:  RNA       Date:  2006-01-23       Impact factor: 4.942

6.  Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription.

Authors:  James Thompson; Tatyana Lepikhova; Neus Teixido-Travesa; Maria A Whitehead; Jorma J Palvimo; Olli A Jänne
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

7.  The role of the Brr5/Ysh1 C-terminal domain and its homolog Syc1 in mRNA 3'-end processing in Saccharomyces cerevisiae.

Authors:  Alexander Zhelkovsky; Yoko Tacahashi; Tommy Nasser; Xiaoyuan He; Ulrike Sterzer; Torben Heick Jensen; Horst Domdey; Claire Moore
Journal:  RNA       Date:  2006-01-23       Impact factor: 4.942

Review 8.  Formation of the 3' end of histone mRNA: getting closer to the end.

Authors:  Zbigniew Dominski; William F Marzluff
Journal:  Gene       Date:  2007-05-04       Impact factor: 3.688

9.  Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.

Authors:  Nathan P Gomes; Glen Bjerke; Briardo Llorente; Stephanie A Szostek; Beverly M Emerson; Joaquin M Espinosa
Journal:  Genes Dev       Date:  2006-03-01       Impact factor: 11.361

10.  Herpes simplex virus type 1 infection leads to loss of serine-2 phosphorylation on the carboxyl-terminal domain of RNA polymerase II.

Authors:  Kathryn A Fraser; Stephen A Rice
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.